{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=17", "query": { "intervention": "Neoadjuvant therapy", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 2079, "total_pages": 208, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T09:26:25.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02997761", "title": "Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult B Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-06-27", "completion_date": "2025-07-17", "has_results": true, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 2, "location_summary": "Los Angeles, California • Sacramento, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02997761" }, { "nct_id": "NCT04506554", "title": "A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma" ], "interventions": [ { "name": "AMVAC + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2020-12-01", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 4, "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04506554" }, { "nct_id": "NCT04289779", "title": "Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Deepak Kilari", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-05-21", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 6, "location_summary": "St Louis, Missouri • Hackensack, New Jersey • Rochester, New York + 3 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04289779" }, { "nct_id": "NCT03117751", "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinase®", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Asparaginase Erwinia chrysanthemi (recombinant)-rywn", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 790, "start_date": "2017-03-29", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 7, "location_summary": "Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03117751" }, { "nct_id": "NCT07221942", "title": "Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Unresectable Urothelial Carcinoma", "Advanced Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2026-01-23", "completion_date": "2029-09-03", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221942" }, { "nct_id": "NCT00004103", "title": "Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "floxuridine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-07", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2011-04-06", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004103" }, { "nct_id": "NCT00193427", "title": "Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-04", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00193427" }, { "nct_id": "NCT02956473", "title": "Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Supine MRI", "type": "DEVICE" }, { "name": "Neoadjuvant Therapy (NAT)", "type": "OTHER" }, { "name": "Ultrasound", "type": "DEVICE" }, { "name": "Mammography", "type": "DEVICE" }, { "name": "Standard of Care", "type": "PROCEDURE" }, { "name": "Standard MRI", "type": "DEVICE" } ], "intervention_types": [ "DEVICE", "OTHER", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 57, "start_date": "2016-11-15", "completion_date": "2022-08", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02956473" }, { "nct_id": "NCT04609046", "title": "Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System" ], "interventions": [ { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-05-24", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 56, "location_summary": "Los Angeles, California • San Francisco, California • Coral Gables, Florida + 43 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04609046" }, { "nct_id": "NCT05051722", "title": "Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Endometrial Cancer", "Cervical Cancer", "Atypical Endometrial Hyperplasia", "Cervical Dysplasia", "Adnexal Mass", "Ovarian Cancer" ], "interventions": [ { "name": "Vaginal Fluid Collection", "type": "DIAGNOSTIC_TEST" }, { "name": "Blood Collection", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3110, "start_date": "2021-08-03", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-31T09:26:25.022Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05051722" } ] }